Thu, Apr 3, 4:20 PM, Zacks
Good News for Keryx - Analyst Blog
Keryx Biopharmaceuticals received good news when the European Medicines Agency (EMA) determined its Marketing Authorization Application (MAA) for lead candidate Zerenex as valid.
Thu, Mar 13, 11:19 AM, Zacks
Wider Q4 Loss at Keryx - Analyst Blog
Keryx Biopharmaceuticals reported a loss of 21 cents in the fourth quarter of 2013, wider than the Zacks Consensus Estimate of a loss of 19 cents per share.